{
    "clinical_study": {
        "@rank": "23267", 
        "arm_group": [
            {
                "arm_group_label": "AK 3012 a for topical use", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "AK 3012 b for topical use", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "AK 3012 c for topical use", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "In this three-armed dose-finding trial 3 AK 3012 topical formulations shall be investigated\n      with respect to safety and efficacy in order to identify the optimal concentration in the\n      topical formulation.\n\n      The main objective of the trial is to determine the optimal concentration of the active\n      agent in the topical formulation as quantified by the change of the number of skin\n      alterations in pre-defined areas in a time period from inclusion in the trial until the end\n      of treatment (3 months) or prior complete healing."
        }, 
        "brief_title": "Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Actinic Keratosis Olsen Grade I/II", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: \u2265 18 years\n\n          -  Gender: male and female\n\n          -  Actinic Keratosis (Olsen grade I/II)\n\n          -  at least 5 actinic keratoses on the scalp, forehead, face, extremities, and/ or\n             decollete\n\n          -  no treatment of the actinic keratoses within the previous 3 months before inclusion\n             in the study\n\n          -  histologic confirmation of the diagnosis actinic keratosis by biopsy\n\n          -  good general condition\n\n          -  normal laboratory values (creatinine, urea, Glutamate-Oxalacetate Transaminase\n             (GOT),Glutamate-Pyruvate Transaminase (GPT), gamma-glutamyl transferase (GGT),\n             Lactate dehydrogenase (LDH)) and blood count at study start not higher than 1.5 x\n             upper norm limit\n\n          -  Female patients must be tested negative for pregnancy before inclusion in the trial.\n             During the trial, female patients have to apply a generally accepted form of birth\n             control (i.e. oral estrogen- and gestagen containing contraceptives; estrogen\n             containing skin plaster/ tape, hormone implant, hormone contraceptive coil,\n             sterilisation; sexual abstinence) or being post-menopausal for at least 2 years.\n\n          -  Willing and able to participate in the screening and all trial specific procedures in\n             compliance with the protocol\n\n          -  Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Known allergy against nonsteroidal antiphlogistics and/ or against excipients of the\n             investigational medicinal product\n\n          -  Presence of immunosuppression\n\n          -  Treatment with 5-fluorouracil, cyclosporine, retinoids, glycolic acid, imiquimod,\n             trichloroacetic acid during the trial or 12 weeks before inclusion in the trial\n\n          -  Continuous treatment with nonsteroidal antiphlogistics with the exception of low-dose\n             acetylsalicylic acid (100 mg) for inhibition of thrombocyte aggregation\n\n          -  Planned treatment with photodynamic therapy during participation in the trial\n\n          -  Pregnancy or lactation\n\n          -  Participation in another clinical trial within 3 months before inclusion in the\n             current trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757613", 
            "org_study_id": "KER-001", 
            "secondary_id": "2012-002529-30"
        }, 
        "intervention": {
            "arm_group_label": [
                "AK 3012 a for topical use", 
                "AK 3012 b for topical use", 
                "AK 3012 c for topical use"
            ], 
            "description": "cutaneous use twice a day", 
            "intervention_name": "AK 3012", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Blaubeuren", 
                        "country": "Germany", 
                        "zip": "89143"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Friedrichshafen", 
                        "country": "Germany", 
                        "zip": "88045"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22391"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Langenau", 
                        "country": "Germany", 
                        "zip": "89129"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Radolfzell", 
                        "country": "Germany", 
                        "zip": "78315"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70190"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70178"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70499"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tuebingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Three-armed, Randomized, Double-blind Dose-finding Trial on Efficiency and Safety of AK 3012 in 3 Different Concentrations in Patients With Actinic Keratosis Olsen Grade I/II", 
        "overall_official": [
            {
                "affiliation": "Eberhard-Karls-Universit\u00e4t T\u00fcbingen", 
                "last_name": "Amir Yazdi, Dr. med", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dolorgiet GmbH & Co. KG", 
                "last_name": "Angelika Trapp", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change of skin alterations during treatment period", 
            "safety_issue": "No", 
            "time_frame": "90 days: Between Visit 0 (day 0) and Visit 3 (day 90)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of visible skin alterations during treatment period", 
                "safety_issue": "No", 
                "time_frame": "90 days: Between Visit 0 (day 0) and Visit 3 (day 90)"
            }, 
            {
                "description": "Tolerability will be assessed on the basis of adverse events", 
                "measure": "Tolerability of the investigated medicinal product", 
                "safety_issue": "Yes", 
                "time_frame": "90  days: Between Visit 0 (day 0) and Visit 3 (day 90)"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "90 days: Between Visit 0 (day 0) and Visit 3 (day 90)"
            }
        ], 
        "source": "Dolorgiet GmbH & Co. KG", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "CenTrial GmbH", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "d.s.h. statistical services GmbH", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dolorgiet GmbH & Co. KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}